FDA Expands Approval of Hympavzi (Marstacimab) for Patients With Hemophilia by Madaline Spencer| Published on: Jun 16, 2026

https://checkrare.com/fda-expands-approval-of-hympavzi-marstacimab-for-patients-with-hemophilia/ The US Food and Drug Administration (FDA) has approved an expanded indication for Hympavzi (marstacimab) to include treatment of patients with hemophilia A or B who are 12 years and older with inhibitors, as well as pediatric patients (ages 6 to 11 years) with or without inhibitors.